Galapagos (GB:0JXZ) has released an update.
Galapagos has entered into a clinical collaboration with Adaptimmune to license and potentially commercialize a new TCR T-cell therapy, uza-cel, for head & neck cancer and other solid tumors, leveraging Galapagos’ decentralized manufacturing platform. The therapy has shown promising results in early trials, with Adaptimmune receiving $100 million initially and up to $465 million in milestone payments plus royalties. This partnership aligns with Galapagos’ strategy to expand its oncology portfolio and offers quicker treatment delivery for patients with significant unmet medical needs.
For further insights into GB:0JXZ stock, check out TipRanks’ Stock Analysis page.
